Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-670 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| VX-670 | EXPERIMENTAL | Participants will receive multiple doses of VX-670. |
| Part A: Single Ascending Dose | EXPERIMENTAL | Participants will be randomized to receive a single dose of different dose levels of VX-670. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will be randomized to receive single dose of placebo matched to VX-670. |
| Part B: Single and Multiple Ascending Dose | EXPERIMENTAL | Participants will be randomized to receive single and multiple doses of different dose levels of VX-670. The dose levels will be determined based on the data from Part A. |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will be randomized to receive single or multiple doses of placebo matched to VX-670. |
| Name | Type | Description |
|---|---|---|
| VX-670 | DRUG | Solution for intravenous administration. |
| Placebo | DRUG | Solution for intravenous administration. |
Key Inclusion Criteria: • Completed study drug treatment in parent study VX23-670-001 (NCT06185764) Key Exclusion Criteria: • History of any illness or any clinical condition as pre-specified in the protocol Other protocol defined Inclusion/Exclusion criteria may apply.
VX-670 is an investigational small molecule being developed for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare genetic disorder. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug is being studied in adult participants with DM1.
VX-670 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting clinical trials to evaluate the safety and efficacy of VX-670 in patients with Myotonic Dystrophy Type 1.
VX-670 is in Phase 2 clinical development. It is being evaluated in two active clinical trials, including a Phase 1/2 study and a Phase 2 long-term safety and efficacy study. The drug is investigational and has not been approved by the FDA or other regulatory agencies.
VX-670 is being studied in two active clinical trials. NCT06185764 is a Phase 1/2 study in adult participants with Myotonic Dystrophy Type 1, enrolling 47 participants across multiple countries. NCT06926621 is a Phase 2 long-term safety and efficacy study with 44 participants. Both trials are placebo-controlled and double-blinded.
VX-670 is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for Myotonic Dystrophy Type 1. The drug is being studied for safety and efficacy, and regulatory approval has not been granted.